# Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic Agents

> **NCT00191438** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 300 (—)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** gemcitabine
- **DRUG:** capecitabine
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00191438
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** —
- **Final completion:** 2007-03
- **Target enrollment:** 300 (—)
- **Last updated:** 2007-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00191438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00191438, "Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic Agents". Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/clinical/NCT00191438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*